FDA/Industry Least Burdensome Collaboration To Follow Release Of Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA will meet with industry to discuss the agency's implementation of least burdensome requirements for premarket submissions, following the pending release of a draft guidance document.
You may also be interested in...
FDA Approach To Least Burdensome Critiqued By Device Industry Task Force
FDA's use of postmarket studies as a condition of approval for two transmyocardial revascularization devices is a fitting example of how to apply the "least burdensome" principles to the device review process as mandated by the 1997 FDA Modernization Act, suggests a coalition of medical device organizations.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.